Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02405026 · ClinicalTrials.gov registry record

Determine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients

A clinical trial of Asthma and HIV, sponsored by Duke University.

Completed
Registry status
83
Enrollment target
1
Study location

NCT02405026: Completed study of Asthma and HIV, sponsored by Duke University.

NCT02405026 is a study of Asthma and HIV that has completed, run by Duke University. The registered enrollment target is 83 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02405026, a study of Asthma and HIV, has completed, sponsored by Duke University.

COMPLETED
Registry status
83 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the prevalence and severity of asthma in patients with HIV. To determine the immunological phenotype of HIV-infected patients with asthma.

Primary Outcome

Assessed through Asthma control questionnaire, pulse oximetry, FeNO, Spirometry, Methacholine challenge, Induced sputum for differential, serum periostin, questionnaires

Conditions Studied

Study Locations (1)

North Carolina

  • Duke Asthma Allergy and Airway Center - Durham

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2014-12
Est. Completion 2017-07
Duke University

1,725 total trials

What the finished NCT02405026 record still lists

NCT02405026 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 0 interventions.

NCT02405026 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02405026 about?

NCT02405026 is a clinical study titled "Determine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients". The purpose of this study is to determine the prevalence and severity of asthma in patients with HIV. To determine the immunological phenotype of HIV-infected patients with asthma.

What is the current status of trial NCT02405026?

This trial is currently completed. The enrollment target is 83 participants. The study started on 2014-12. Estimated completion is 2017-07.

What conditions does trial NCT02405026 study?

This clinical trial studies the following conditions: Asthma, HIV.

Who is sponsoring clinical trial NCT02405026?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02405026 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02405026's enrollment target sits among peer trials

83 223rd of 374 higher than 152 of 374 other Asthma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02974647 · 83 participants · Phase 2

    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

  • NCT03919292 · 83 participants · Phase 1

    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

  • NCT04626674 · 83 participants · Phase 1

    A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  • NCT05277168 · 83 participants · Phase 1

    A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02405026, the US trial registry maintained by the National Library of Medicine. NCT02405026 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.